Company: SNY
Filing Date: 2025-10-27
Form Type: 424B5
Source: 0001193125-25-250786
Chunk: 28

Company: Sanofi
Filing Date: 2025-10-27
Form: 424B5
Chunk 28
---
 least two-thirdsof the voting rights expressed within that class, and provided certain requirements are met, the plan would be imposed upon the dissenting creditors of such class through a cram-down. Should the plan be rejected by one or more such class(es), the competent French court may nevertheless adopt it and impose it upon the dissenting creditors and classes (through a cross-class cram down sanctioned by such court), provided certain requirements are met such as compliance with the absolute priority rule called under French law règle de la priorité absolue(subject, however, to the court’s possible authorization to deviate from the absolute priority rule). However, if the debtor’s recovery is clearly impossible, the relevant court can order a sale of the business as a going concern or open or, as the case may be, convert the then outstanding proceedings into, judicial liquidation proceedings ( liquidation judiciaire). Practically, it is highly unlikely that the holders of the notes, as unsecured creditors, could be repaid in full for their claims within those contexts. Therefore, certain provisions of the indenture may not be enforced or enforceable by the trustee or holders of notes issued under this prospectus supplement and the attached prospectus in case of opening of court-assisted pre-insolvencyproceedings or court-administered insolvency proceedings under French law regarding Sanofi S.A. Moreover, the commencement of insolvency proceedings against Sanofi S.A. would have a material adverse effect on the market value of the notes. As a consequence, any decision(s) taken by a class of Affected Parties or the court could negatively and significantly impact the holders of notes and cause them to lose all or part of their investment, should they not be able to recover all or part of the amounts due to them by Sanofi S.A. You may be unable to recover in civil proceedings for U.S. securities laws violations. Sanofi is a limited liability company ( société anonyme) organized under the laws of France and most of our officers and directors reside outside of the United States. In addition, a substantial portion of our assets is located in France. Accordingly, it may be difficult for investors to obtain jurisdiction over us, our non-U.S.resident officers and directors in courts in the United States, as well as to obtain evidence from any French citizen or any individual being resident in France or any director, officer, representative, agent or employee of a legal person, having its registered office or an establishment in a territory of France, in connection with those actions and enforce in France